Heart Disease News and Research

Latest Heart Disease News and Research

Geron reports net loss of $16.6M for first-quarter 2010

Geron Corporation today reported financial results for the three months ended March 31, 2010.

29 Apr 2010

Study examines lifestyle-related causes of death in AIDS patients

The study, by researchers from the University of Bristol and a large group of international collaborators, examined data from the Antiretroviral Therapy Cohort Collaboration (ART-CC) which involved nearly 40,000 patients who started ART between 1996 and 2006 in Europe and North America.

29 Apr 2010

ECRI Institute's recommendations for controlling CT radiation dose

The benefits of computed tomography (CT) have increased greatly over the past decade. Now twice as powerful, it offers dynamic images of anatomy, including the beating heart. Future advancements promise to deliver even more clinical benefits. However, CT has always had a downside: it can deliver high radiation doses to patients, putting them at increased risk of developing cancer.

29 Apr 2010

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, today reported financial results for the second quarter ended March 31, 2010.

29 Apr 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Renowned cardiologists to discuss latest research on Hypertrophic Cardiomyopathy at HCMA symposium

Hypertrophic Cardiomyopathy (HCM), the genetic disease in which the muscle of the heart thickens in the absence of an apparent cause, is the leading cause of sudden death in children and young adults. HCM accounts for 40 percent of all deaths on athletic playing fields across the U.S.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Obama's debt commission to consider Medicare cuts, new health care law

President Obama's bipartisan debt commission met Tuesday to discuss ways to reduce the federal deficit. The President said that everything was up for discussion, including provisions of the federal health care law, and entitlement programs like Medicare and Social Security.

29 Apr 2010

Vascular surgeon successfully bypasses torn aorta

Rhonda Mullen was 38 years old and in perfect health when she suddenly felt a searing pain between her shoulder blades. A few hours later, Mullen was being wheeled into an operating room at Loyola University Hospital for emergency surgery to repair an unusual tear in her aorta, the body's main blood vessel.

29 Apr 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

Merge Healthcare completes merger agreement with AMICAS

Today's successful close of the merger agreement between Merge Healthcare Incorporated and AMICAS, Inc. creates a leading medical imaging software and healthcare IT solutions provider with strong customer relationships, innovative solutions, significant cross selling capabilities, and a solid international presence.

29 Apr 2010

Celera reports net loss of $12.5M for first-quarter 2010

Celera Corporation today reported net revenues of $31.4 million for the first quarter of 2010 that ended March 27, 2010, compared to $45.7 million in the prior year quarter. For the first quarter of 2010, Celera reported a net loss $12.5 million, or $0.15 per share, compared to a net loss of $1.4 million, or $0.02 per share, for the prior year quarter.

28 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

AAP testimony asks CDC DOH to include periodontal surveillance as part of strategic priorities

The American Academy of Periodontology was recently invited to provide testimony to the Centers for Disease Control and Prevention's Division of Oral Health as part of the strategic planning process for 2011 through 2014.

28 Apr 2010

Heart Disease News and Research

Latest Heart Disease News and Research

Geron reports net loss of $16.6M for first-quarter 2010

Study examines lifestyle-related causes of death in AIDS patients

ECRI Institute's recommendations for controlling CT radiation dose

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Study calls for optimized medical treatment for older patients with advanced lung cancer

A new approach for treating neurological and degenerative disorders

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Renowned cardiologists to discuss latest research on Hypertrophic Cardiomyopathy at HCMA symposium

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Tumor cell factories may be difficult to defeat: Researchers

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Obama's debt commission to consider Medicare cuts, new health care law

Vascular surgeon successfully bypasses torn aorta

Investigators study Pioglitazone and Vitamin E for treatment of NASH

Merge Healthcare completes merger agreement with AMICAS

Celera reports net loss of $12.5M for first-quarter 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

AAP testimony asks CDC DOH to include periodontal surveillance as part of strategic priorities

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Heart Disease News and Research

Latest Heart Disease News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in